StreetInsider.com News Articles

Kyntra Bio to Report Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 09:00:00 -0400

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast Presentation
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio

Kyntra Bio to Report Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 09:00:00 -0400

Kyntra Bio to Report Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 09:00:00 -0400

Kyntra Bio to Report Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 09:00:00 -0400

Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35

Mon, 06 Jul 2026 16:14:46 -0400

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Outperform rating and a price target of $35.00.

The analyst comments "We initiate coverage of Kyntra Bio with an Outperform rating and $35 PT, given our optimism for lead programs FG-3246 and FG-3180 to address the persistent unmet need among ~65K US-based mCRPC patients, particularly in PSMA-low/-negative and post-ARPI settings. As the only CD46-directed ADC and the only non-PSMA ADC with a PET CDx (FG-3180), FG-3246 is uniquely positioned against the PSMA-dominated mCRPC pipeline, with potential to unlock value for KYNB on Ph2 monotherapy interim data in 4Q26.

Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35

Mon, 06 Jul 2026 16:14:46 -0400

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Outperform rating and a price target of $35.00.

Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35

Mon, 06 Jul 2026 16:14:46 -0400

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Outperform rating and a price target of $35.00.

Oppenheimer Starts Kyntra Bio (KYNB) at Outperform, PT $35

Mon, 06 Jul 2026 16:14:46 -0400

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Outperform rating and a price target of $35.00.

Kyntra Bio presents roxadustat data showing transfusion improvements in MDS

Thu, 11 Jun 2026 16:06:22 -0400

Kyntra Bio (NASDAQ: KYNB) announced data from its Phase 3 MATTERHORN trial showing roxadustat improved transfusion independence in patients with lower-risk myelodysplastic syndromes and high transfusion burden. The data was presented at the European Hematology Association Congress in Stockholm.

In a post-hoc analysis of patients with high transfusion burden, defined as requiring at least 4 units of red blood cells per 8-week period for two consecutive periods, roxadustat demonstrated higher rates of transfusion independence compared to placebo across 8, 12, and 16-week periods. The analysis included 37 patients who met the high transfusion burden criteria from the 140 total trial participants.

The

Kyntra Bio presents roxadustat data showing transfusion improvements in MDS

Thu, 11 Jun 2026 16:06:22 -0400

The

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Thu, 11 Jun 2026 16:05:00 -0400

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo
Similar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease
Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA)

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE)

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Thu, 11 Jun 2026 16:05:00 -0400

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo
Similar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease
Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA)

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE)

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Thu, 11 Jun 2026 16:05:00 -0400

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo
Similar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease
Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA)

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE)

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

Thu, 11 Jun 2026 16:05:00 -0400

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo
Similar rates of TI for patients treated with roxadustat were observed in both ring sideroblast positive (RS+) and ring sideroblast negative (RS-) disease
Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the Food and Drug Administration (FDA)

SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE)

Rodman & Renshaw Starts Kyntra Bio (KYNB) at Buy

Tue, 09 Jun 2026 07:01:22 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Buy rating and a price target of $30.00.

The analyst comments "We are initiating coverage of Kyntra Bio with a BUY rating and $30 price target based on the company's first-in-class CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration-resistant prostate cancer (mCRPC), a Phase 3-ready oral HIF-PHI program in myelodysplastic syndrome anemia with FDA Orphan Drug Designation, and a balance sheet that remains strong relative to the company's current equity value. Formerly known as FibroGen, Inc., Kyntra completed a decisive transformation in 2025, including the $220

Rodman & Renshaw Starts Kyntra Bio (KYNB) at Buy

Tue, 09 Jun 2026 07:01:22 -0400

Rodman & Renshaw analyst Michael King Jr. initiates coverage on Kyntra Bio (NASDAQ: KYNB) with a Buy rating and a price target of $30.00.

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 11 May 2026 16:05:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026

Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 11 May 2026 16:05:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026

Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 11 May 2026 16:05:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026

Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 11 May 2026 16:05:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026

Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 11 May 2026 16:05:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026

Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 11 May 2026 16:05:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026

Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 11 May 2026 16:05:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026

Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 11 May 2026 16:05:00 -0400

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026

Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements

Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug

Kyntra Bio to Report First Quarter 2026 Financial Results

Mon, 04 May 2026 16:05:00 -0400

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

Conference Call and Webcast Presentation

Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a